- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Astemizole: A Long-Acting, Nonsedating Antihistamine
Search this article
Description
<jats:p> Astemizole is a long-acting, highly selective histamine<jats:sub>1</jats:sub>-receptor antagonist with minimal central and anticholinergic effects. Comparison studies have shown astemizole to be equal or superior to currently available antihistamines, beclomethasone nasal spray, and cromolyn sodium in relieving allergic symptoms of seasonal and perennial allergic rhinitis. Other uses include treatment of allergic conjunctivitis and chronic urticaria. Astemizole is not as effective for treatment of acute allergic symptoms because of its delayed onset of action. Astemizole and its active metabolite, desmethylastemizole, have long elimination half-lives permitting once-daily dosing. The incidence of sedation is lower than with conventional antihistamines, but increased appetite and weight gain do occur. Astemizole should be useful for both maintenance and prophylactic therapy in patients with chronic allergic conditions who cannot tolerate the sedative or anticholinergic effects of conventional antihistamines. </jats:p>
Journal
-
- Drug Intelligence & Clinical Pharmacy
-
Drug Intelligence & Clinical Pharmacy 21 (12), 947-953, 1987-12
SAGE Publications
- Tweet
Details 詳細情報について
-
- CRID
- 1361699993767506048
-
- ISSN
- 00126578
-
- Data Source
-
- Crossref